The Financial Post reports in its Thursday edition that Africa's largest drugmaker expects to get approval in Canada for its generic GLP-1 obesity treatment by September, potentially giving it an early start in a key market after Novo Nordisk's Ozempic patent expired. A Bloomberg dispatch to the Post says Aspen Pharmacare Holdings is targeting regulatory approval between May and September for its copycat version of semaglutide, the key ingredient in Ozempic, chief executive officer Stephen Saad told Bloomberg. The Durban, South Africa, company hopes to be among the first to market in Canada, helping it in other nations that look to established regulators as benchmarks. "You want to be within, say, six months of a first launch, to be part of market formation," Mr. Saad said Tuesday, adding that Canada would likely be the first market for its GLP-1 product.